Introduction NF1 (OMIM #162200) is a rare autosomal dominant genetic condition that targets the nervous system resulting in neurofibromas, typically benign tumors that affect the brain, spinal cord, nerves, and skin. Disease incidence estimations range from 1 in 2,500 to 4,000 births and affect males and females in equal frequencies. Individuals may genetically inherit the disorder, but approximately 50% of mutations occur de novo in the NF1 gene encoding neurofibromin tumor suppressor protein on chromosome 17q11.2 1 .
The mutation rate at this locus is among the highest rate known for any gene in humans.
This degenerative disease is characterized by a wide spectrum of clinical manifestations such as anomalous skin hyperpigmentations (café-au-lait spotting), neurofibromas, bone growth abnormalities, learning deficits, and developmental delays. The clinical symptoms are diverse in phenotypic manifestation as well as symptomatic severity. These factors present challenges to the diagnosis of NF1, which is contingent upon guidelines enumerated by the National Institutes of Health (NIH At patient age of nineteen months, six-month surgery follow-up radiographs showed significant migration of the inserted percutaneous rod hardware. The most distal aspect of the rod in the inferior tibia migrated to the plantar skin overlying the calcaneus ( Figure   5 ). Moderate lucency about the calcaneus was noted, indicating significant rod motion.
The area of PA in the mid-diaphysis of the tibia did not show any significant regeneration of bone in the graft site and the position of the bone structures remained unchanged. A corrective operation was immediately undertaken through distal left tibia via a plantar heel approach (Figure 1 ).
At present condition, twenty-two month pediatric and radiologic evaluation shows stable but slow healing of fracture and progressive straightening of leg. Radiographs show improved solidified osteogenesis at the proximal tibia, however bone fails to show robust ! healing or bridging at the original PA site (not shown, summarized in Figure 1 This case is of particular medical interest due to the unusual phenotype of the neurofibromatosis. The disorder manifested itself in our patient predominantly through orthopedic -rather than neurologic -symptoms. Furthermore, this case is unique in that initial fracture occurred at four months of age, indicating a particularly aggressive congenital disorder despite absence of prior family history of either PA or NF1. Our patient was a small, light infant not bearing full weight on her long bones. Due to the severely dysplastic and bowed nature of her tibia and fibula, fracture occurred with minimal force (presumably the downward bounce on the bowed leg). Such minimal activity typically does not yield fractures especially in normal infants. This case illustrates one extreme end of the spectrum for bone dysplasia severity.
Since in prior reported cases of NF1, PA was invariably secondary to NF, our patient did not present enough early symptoms to receive NF1 diagnosis at 4 months when she first manifested PA. Up to one-half of children who are first seen by orthopedists for anterolateral bowing of the tibia will not have a diagnosis of neurofibromatosis 13 .
Although the NIH criteria for suspecting NF1 provide high value, there is a need for further improvement, as up to 35% of children with NF1 remain undiagnosed by the age ! of five 14, 15 . For example, one of the primary diagnosis criterions stipulates multiple café-au-lait spots yet 10% of the general healthy population has one or two café-au-lait spots 6 .
Due to these overlapping symptoms, NF1 diagnosis becomes muddled and may only be definitively established with exome sequencing. It is thus our recommendation that any suspected case of NF1 -due to particular severe, early, or primary PA -may benefit from accelerated NF1 exome sequencing leading to better diagnosis of ulterior problems and improved management of patient outcomes. Therefore expansion of existing NIH guidelines is warranted to accommodate such aggressive cases to improve presymptomatic detection of treatable manifestations, reduce risk of fracture prior to breakage and to improve ultimate prognosis of this rare condition. 
